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Abstract
Objective: The objective of this selective EBM review is to determine whether or not “Does
exogenous melatonin improve quality of sleep in patients experiencing sleep disturbances
secondary to chronic diseases?”
Study Design: Three Randomized, placebo-controlled studies (RCT) published in 2010, 2013
and 2008.
Data Sources: All RCTs searched and located using PubMed database.
Outcomes Measured: Clinical outcome for all three articles using quality of sleep or quality of
life questionnaires such as the Leeds Sleep Evaluation. All of which evaluated POEMs, and were
self reported by participants.
Results: In a randomized control study (RCT) by Serfaty et al, sleep quality improved by
lessening time needed to get to sleep, but was not specific to either the experimental or placebo
group. The RCT by Russcher et al. also indicated that there was no significant increase in quality
of life for participants given exogenous melatonin. Only the RCT by Koch et al. showed
significant improvement in quality of sleep with the use of melatonin in participants by
decreasing time needed to fall asleep, increasing sleep time and improving overall quality of
sleep.
Conclusions: The data obtained was insufficient to conclusively support the use of exogenous
melatonin to alleviate sleep disturbances secondary to chronic disease. Two of the three RCTs
included in this systematic review were not able to show significant data in support of the
positive effects of exogenous melatonin on sleep patterns.
Keywords: melatonin, depression, and hemodialysis
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Introduction
Melatonin plays an important role in the sleep regulation of human beings. It is a
hormone that modulates sleep/wake cycles and can greatly diminish quality of life if levels are
disturbed. It is one of the main external indicators of time during sleep/wake cycles and is
stimulated by darkness and inhibited by light.1 Many diseases such as chronic kidney disease and
depression can cause sleep disturbances due to changes in circadian rhythms. More specifically,
affective disorders such as depression affect circadian rhythms by modulating melatonin levels.1
In patients suffering from chronic kidney disease, hemodialysis can impede the nocturnal rise in
melatonin concentration.2 Exogenous melatonin is widely available for purchase as an over the
counter supplement in the United States, and is fairly inexpensive. This paper analyzes three
randomized controlled studies that study the effects of exogenous melatonin on sleep
disturbances caused secondarily due to chronic diseases.
Sleep disturbances consume a great deal of healthcare resources worldwide every year.
Although there is not much data regarding the number of healthcare visits per year caused by
sleep disturbances, one article noted that patients reporting less than 5 hours of sleep per night
had the highest healthcare utilization when compared to other groups with better quality of
sleep.3 The same article also noted that sleep complaints are underreported by patients, and
underdiagnosed by physicians, and therefore the healthcare utilization due to sleep disturbances
is much higher than reported.3 Although not specific to patients suffering from chronic diseases,
one study noted that general sleep disturbances and associated health effects cost an estimated
$450 million dollars annually in Australia alone.4 Due to the large impact of sleep disturbances
on the depletion of healthcare resources, the efficacy of exogenous melatonin as a treatment for
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sleep disturbances caused by they many different existing chronic disease is an important area of
study.
Currently there are a wide variety of methods used to treat sleep disturbances. Good sleep
hygiene should be considered the first and simplest method of helping to lessen such sleep
disturbances. Some practices that may improve sleep hygiene include, having a regular sleep
schedule, avoiding caffeinated beverages or smoking in the evening, adjusting your sleep
environment to decrease stimuli, and only exercising at least 4-5 hours before scheduled sleep.5
Other non-pharmacological approaches can also be therapeutic towards improving quality of
sleep. One such approach is to use relaxation techniques such as progressive muscle relaxation
and relaxation response therapy that should implemented right before each intended sleeping
period.5 Such relaxation techniques are simple to teach patients, and can be done independently.
Cognitive behavioral therapy, which can be conducted traditionally through in person sessions or
even via telephone or computer, may be an appropriate treatment for those individuals who need
assistance and guidance. The most commonly used method to treat sleep disturbances are
pharmacologic agents however. There are many different classes that can be utilized, including
but are not limited to benzodiazepines, non-benzodiazepines, and melatonin agonists.6 Some
common benzodiazepines used are triazolam, lorazepam, tenazepam, and alprazolam. Nonbenzodiazepines have newer, more advertised agents such as Zolpidem. Melatonin agonists
agents include Ramelteon, and have shown to significantly improve general sleep latency.5
Overall many studies, including the three RCTs that this paper focuses on, evaluate the
effects of exogenous melatonin on the many patient groups with disturbed circadian rhythms.1 In
some previous studies, short-term supplementation has been shown to alleviate problems, but the
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studies included in this systematic review evaluate long term supplementation on patients with
chronic disease and its results.
Objective
The objective of this selective EBM review is to determine whether or not “Does
exogenous melatonin improve quality of sleep in patients experiencing sleep disturbances
secondary to chronic diseases?”
Methods
This selective EBM review analyzed 3 randomized control studies that evaluated the
aforementioned objective. The population criteria that were set for the purpose of this systematic
review included the following: participants ages 18 and older, diagnosis of a chronic disease
such kidney disease or major depression, and reported subjective findings of sleep disturbances.
All three randomized controlled studies used exogenous melatonin as the intervention addressed,
and used a placebo tablet for the comparison control group. The main outcome that is evaluated
in this paper is quality of sleep based on sleep questionnaires values.
This writer used PubMed as the sole data source to find the three studies utilized in this
paper, using keywords of melatonin, depression, and hemodialysis. The search parameters used
were: English language, human species data, and published in peer reviewed journal in the past
10 years. Types of studies searched included only randomized control studies, which measured
outcomes that could be classified as a POEM or Patient Oriented Evidence that Matters.
Exclusion criteria included any studies in which participants used melatonin previously, studies
that tested melatonin along with other pharmacological methods, or studies including participants
not suffering from chronic diseases. The search conducted also verified that there are no previous
Cochrane reviews or systematic reviews published on this objective, or any published by other

Thomas, Effects of Exogenous Melatonin,

4

previous students. All studies used in this paper used p-values to report statistics. The
demographics and characteristics of the included studies can be seen in Table 1.
Table 1 - Demographics & Characteristics of included studies
Study
Type
#
Age
Inclusion
Exclusion Criteria
Pts (yrs.) Criteria
Serfaty1
Double 33
18-65 Diagnostic and
Another axis 1
(2010)
blind
Statistical
diagnosis,
RCT
Manual of
delusions or
Mental
hallucinations,
Disorders
ECT within 6
classification for months, hypnotic
major
medications,
depression; a
recent change in
score of >17 on dose or type of
BDI; self
psychotropic
reported sleep of medication within
1 hour less than 4 weeks, history of
normal at least 3 ETOH abuse
days per week
Russcher2 Double 67
18-85 Patient in age
Current melatonin
(2013)
blind
group with >3
use, Known
RCT
months of
hypersensitivity to
hemodialysis
melatonin, sever
with adequate
psychological or
dialysis efficacy; neurological
subjective sleep disease, unstable
problems at
angina pectoris,
baseline; mean
NYHA class IV
sleep onset
heart failure,
latency > 15
pregnancy,
min.
participation in
another clinical
trial 1 month prior
to start of this
study
Koch6
Double 20
18-85 Pts in age group Pts with prior use
(2008)
blind
on stable
of melatonin, use
RCT
hemodialysis (> of hypnotics that
3 months)
could not be
stopped, or sever
psychological or
neurological
disease.

W/D Interventions
2

Slow release
exogenous
melatonin
(6 mg)

25

3 mg IR
melatonin
QD at 22:00
hrs.

4

Melatonin 3
mg QD at
22:00 hrs.
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Outcomes Measured
Outcomes measured in the three studies included in this paper were POEMS. In the
Serfaty et al. RCT, subjective measures of sleep were collected using the Leeds Sleep Evaluation
Questionnaire which measured: getting to sleep, quality of sleep, awakening from sleep and
behavior following waking.1 In the Russcher et al. RCT study, sleep-wake characteristics were
measured from the Dutch sleep disorders questionnaire which recorded estimated sleep time,
daytime function, sleep onset latency, wake periods during the night, feeling rested during
daytime, and subjective sleep quality.2 In the Koch et al. RCT study, sleep disturbances were
measured by quality of life questionnaire.6
Results
In the study by Serfaty et al., out of the 203 interviewed potential participants, 33 patients
were recruited to the study.1 16 of the participants were referred to the study by their general
practitioner, 13 were identified by databases, and 4 were self referred.1 Two participants dropped
out immediately due to feeling much better. Participants were randomly assigned to one of two
groups, which was done by independent coordinator ensuring a double-blind trial.1 The LSEQ
tested many parameters for sleep and determined that sleep improved for whole group, but not
specifically to the experimental group with melatonin. General Linear Modeling was used in this
study to measure the differences between the placebo and melatonin groups which showed that
there was a significant reduction in time getting to sleep (F = 6.6, d.f. = 3.2, P < 0.001) and
improved quality of sleep (F = 4.8, d.f. = 3.6, P < 0.002) with melatonin.1 Other than the
previous two values mentioned, no other significant differences in sleep were seen in either
group.1
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In the Serfaty RCT, some patients reported adverse effects in both the melatonin and
placebo groups. The adverse effects reported are shown in Table 2.
Table 2 – Adverse Effects seen in Serfaty RCT1
Melatonin Group
Placebo group
Adverse Effect
# of patients
Adverse Effect
# of patients
affected
affected
Vivid dreams
2
Poor sleep
2
Daytime Somnolence
1
Daytime Somnolence
1
Fuzzy feeling
1
Vivid Dreams
1
Headaches
1
The Russcher et al. RCT included sixty-seven daytime hemodialysis patients, forty-two
of whom completed the study.2 Twenty-five patients did not complete the study, reasons for
which can be seen in Table 3. This RCT sought patients who had been on hemodialysis for at
least 3 months, and reported subjective sleep problems with a minimum mean sleep onset latency
of > 15 minutes.2 Quality of life was the main topic investigated in this study, using a
questionnaire that was independently filled out by the participants on a daily basis after sleep
periods. After analyzing the questionnaire data, the researchers concluded that there was no
discernable differences in vitality between the melatonin and placebo groups over the 12 months
(difference -1.9%, 95% CI – 12.6, 8.7).2 Some incidental differences were found which
illustrated increased general mental health (difference 9.3%, 95% CI -0.1, 18.7, P = 0.052), and
decreased physical functioning (-11.4%, 95 CI -12.6, 8.7) in the melatonin group over 12
months.2 All other parameters tested by the quality of life questionnaire did not differ between
melatonin and placebo groups. No side effects of melatonin were reported.2
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Table 3 – Patient Dropouts in Russcher et al. RCT2
Melatonin Group
Placebo group
Reason for leaving # of patients Reason for leaving # of patients
Died
3
Died
3
Transplantation
3
Transplantation
3
Withdrawal
Nocturnal dialysis

4
1

Withdrawal
Nocturnal dialysis

6
1

Home dialysis

1

The RCT by Koch et al. had a total of twenty-four participants at baseline, but 20
participants remained at the end of the 18-week period.6 Of the 4 participants lost, two patients
died, one withdrew from having dialysis, and one was removed due to non-compliance.6
Throughout the course of the study, no adverse effects of melatonin were reported.
Koch et al. evaluated quality of sleep using a sleep questionnaire that analyzed daytime
function and subjective sleep experience. The results of the questionnaire from patients
undergoing hemodialysis are summarized in Table 4. The data illustrated that less time was
necessary to fall asleep for patients on daytime dialysis when using melatonin over the placebo
group (P = 0.04).6 Overall sleep time increased as well on nights after dialysis (P=0.01), and
nighttime awakenings decreased after dialysis (P=0.03).6 No adverse effects were reported.
Table 4 – Sleep Questionnaire results from Koch et al.6
Parameters
Median Placebo
Daytime napping (min)
30
Sleep onset latency (min)
45
Wake periods (min)
30
Sleep time (min)
345

Median Melatonin
0
15
25
480

Discussion
Of the three RCT studies incorporated in this paper, only the Koch et al. RCT showed
significant improvement due to the use of supplemental exogenous melatonin in those suffering
with chronic diseases. The RCT by Serfaty et al. did not show any significant difference in sleep
quality between both the melatonin and placebo groups, despite very similar demographic
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factors, depression severity, and randomization. Serfaty et al. also discusses a limitation in which
the values from the sleep diary/questionnaire could unreliable as they may have not been always
accurately reported by the patients.1 It can be recommended in this RCT that such subjective
findings be recorded or collected by a third party instead of having patients answering the
questionnaires independently. The RCT by Russcher et al. also did not show any significant
positive effects of using exogenous melatonin. The authors found that there was no improved
quality of life based on the quality of life questionnaire it utilized, but did suggest using a higher
dosage of melatonin could produce more favorable results.2 Limitations of the Russcher study
also include the higher than expected drop out rate of participants (37%), as this could have
affected the data in a negative manner. The authors only expected to have a 25% drop out rate,
and argued that the results obtained could be due to the study’s loss of power rather than the
inefficacy of exogenous melatonin to alleviate sleep disturbances.2
As this selective EBM review analyzes the efficacy of exogenous melatonin on sleep
disturbances secondary to chronic disease, future research should be done on the effect of
exogenous melatonin on diseases other than CKD and depression. The search conducted by this
author on PubMed did not reveal many RCTs regarding the efficacy on exogenous melatonin in
general, and future RCT and researchers should seek out other chronic diseases that can impact
the circadian rhythms of humans.
Conclusion
After reviewing each of the three RCT studies discussed in this systematic review, there
is not enough data for a conclusive decision on if exogenous melatonin is effective in alleviating
sleep disturbances in those suffering from chronic diseases. Although all three RCTs
incorporated in this paper had rigorous methodology and adequate sample sizes, 2/3 studies did
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not find significant results supporting a positive change in sleep patterns in participants. The
Koch et al. RCT did show definitive results that indicated exogenous melatonin improved quality
of sleep by reducing time needed to get to sleep, increase in sleep time, and improvement in
sleep quality. Limitations of this systematic review include one study that had a high number of
withdrawals (25), biases of the participants filling out the subjective sleep questionnaires
themselves, and the overall use of the standard dose of melatonin versus a larger dose.
Therefore, further research should be conducted on the benefit of melatonin on patients suffering
from chronic kidney disease, but should also include many different types of dialysis rather than
only patients undergoing daytime treatments. Future studies can also investigate more long-term
effects of melatonin and the effects of a larger does of melatonin, as all three RCTs in this paper
utilized traditional doses of melatonin and did not exceed a timeline of 12 months.
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